Oral NSAID preparation for horses

2015 ◽  
Vol 176 (26) ◽  
pp. 685.1-685
Keyword(s):  
Oral Nsaid

Relationship between apoptosis, angiogenesis and colon-26 tumour growth after oral nsaid treatment

1999 ◽  
Vol 59 (1-6) ◽  
pp. 61
Author(s):  
Joanne R. Brown ◽  
Michael P. Seed ◽  
Claire N. Freemantle ◽  
Paul R. Colville-Nash ◽  
Dean Willis ◽  
...  
Keyword(s):  
Tumour Growth ◽  
Nsaid Treatment ◽  
Oral Nsaid ◽  
Colon 26

Evidence-based protocols for oral NSAID challenges

2006 ◽  
Vol 148 (5) ◽  
pp. 704-705 ◽  
Author(s):  
Donald D. Stevenson ◽  
Katherine M. Woessner ◽  
Ronald A. Simon ◽  
Jennifer A. Namazy ◽  
David M. Lang
Keyword(s):  
Evidence Based ◽  
Oral Nsaid

scholarly journals Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review

2010 ◽  
Vol 37 (6) ◽  
pp. 1236-1243 ◽  
Author(s):  
UNA E. MAKRIS ◽  
MINNA J. KOHLER ◽  
LIANA FRAENKEL
Keyword(s):  
Older Adults ◽  
Adverse Effects ◽  
Case Reports ◽  
Nonsteroidal Antiinflammatory Drugs ◽  
Withdrawal Rate ◽  
Treatment Modalities ◽  
Application Site ◽  
Topical Nsaid ◽  
Antiinflammatory Drugs ◽  
Oral Nsaid

Objective.To systematically review the literature on reported adverse effects (AE) associated with use of topical nonsteroidal antiinflammatory drugs (NSAID) in older adults with osteoarthritis (OA).Methods.A systematic search of Medline (1950 to November 2009), Scopus, Embase, Web of Science, Cochrane databases, Dissertation and American College of Rheumatology meeting abstracts was performed to identify original randomized controlled trials, case reports, observational studies, editorials, or dissertations reporting AE from topical NSAID in older adults with OA. Information was sought on study and participant characteristics, detailed recording of application site, and systemic AE as well as withdrawals due to AE.Results.The initial search yielded 953 articles of which 19 met eligibility criteria. Subjects receiving topical NSAID reported up to 39.3% application site AE, and up to 17.5% systemic AE. Five cases of warfarin potentiation with topical agents were reported, 1 resulting in gastrointestinal bleeding. In formal trials, the withdrawal rate from AE ranged from 0 to 21% in the topical agents, 0 to 25% in the oral NSAID, and 0 to 16% in the placebo group.Conclusion.Although topical NSAID are safer than oral NSAID (fewer severe gastrointestinal AE), a substantial proportion of older adults report systemic AE with topical agents. The withdrawal rate due to AE with topical agents is comparable to that of oral NSAID. Given the safety profile and withdrawal rates described in this study, further data are needed to determine the incremental benefits of topical NSAID compared to other treatment modalities in older adults with OA.

scholarly journals POS1179 POST COVID ARTHRITIS; REACTIVE ARTHRITIS OR RHEUMATIC DISEASE FLARE OR BOTH

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 871.1-871
Author(s):  
F. Fayed ◽  
E. Abdelkarim
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Reactive Arthritis ◽  
Viral Infections ◽  
Past History ◽  
Musculoskeletal Symptoms ◽  
Oral Nsaid ◽  
History Of ◽  
A Prospective Study ◽  
New Onset

Background:Reactive arthritis (ReA) is an emerging arthritis after viral infection especially respiratory and gastrointestinal related viruses. In 2020, SARS-COV2 virus is sweeping worldwide with diverse symptoms and prolonged post-Covid manifestations in which are arthralgia and myalgia are frequently present for days and even months. Interestedly, arthritis in covid era is a part of ReA or a flare of autoimmune disease, it is challenging.(1)Objectives:Our objective was to determine the frequency of musculoskeletal symptoms with SARS-COV2 virus and after recovery as well as its relation to autoimmune diseases flares.Methods:A Prospective study was done on 241 patients who admitted to the Rheumatology clinic from March 2020 to January 2021, complaining from new onset of musculoskeletal symptoms. Detailed history, Examination of systems including Musculoskeletal, laboratory investigation, past history of existing rheumatic disease, and history of infection with covid 19.Results:Among 241 patients with median age 34.4, 36.92% had an existing Rheumatic disease while 63.08% are not. Moreover, 39% of patients had a post history with covid 19 within weeks. The most frequent Musculoskeletal symptoms are myalgia (74.56%), arthralgia (69.36%), and arthritis (10.78%). Furthermore, ReA (Post covid arthritis) accounted (2.07%) especially monoarthritis of Ankle (68.75%) while rheumatic diseases flares (24.48%) as well as new onset rheumatic diseases (39.68%). (p ≤0.001) patients of ReA improved on NSAID and intrarticular injection of glucocorticosteroid.Conclusion:Covid 19 is one of environmental triggers for development of rheumatic disease as well as reactive arthritis post viral infections. ReA is commonly affected the Ankle joint mainly monoarthritis and had improved on oral NSAID and intrarticular injection of Glucocorticosteroid.References:[1]Schett, G., Manger, B., Simon, D. et al. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol16, 465–470 (2020).Disclosure of Interests:None declared.

scholarly journals A Teenager with Severe Asthma Exacerbation following Ibuprofen

2005 ◽  
Vol 33 (2) ◽  
pp. 261-265 ◽  
Author(s):  
G. M. Palmer
Keyword(s):  
Respiratory Disease ◽  
Severe Asthma ◽  
Asthma Exacerbation ◽  
Postoperative Pain Management ◽  
Older Children ◽  
Oral Nsaid ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Severe Asthma Exacerbation ◽  
Nasal Disease ◽  
Asthmatic Reaction

Aspirin-sensitive asthma, aspirin-intolerant asthma, aspirin- (or non-steroidal anti-inflammatory drug [NSAID]) exacerbated respiratory disease are terms for a disorder commonly described as affecting adults aged >30y. With this perception, ibuprofen was administered for postoperative pain management to a 17-year-old boy with allergic rhinitis and previous severe asthma (at a time when well controlled), who then had a severe asthma exacerbation. Analysis of the literature in response to this case highlights four points: 1) NSAID-exacerbated asthma is not only a disorder of adults; it occurs in up to of 2% in asthmatic children, approaching probably 30% in older children with severe asthma and nasal disease. 2) The asthmatic reaction is dose-dependent and can occur with sub-therapeutic doses. Oral NSAID/aspirin challenge should be conducted in an environment where a severe asthma exacerbation can be appropriately managed. 3) The therapeutic use of non-selective [COX-1 preferential] NSAIDs should be avoided when sensitivity is known or suspected in adults and teenagers with severe asthma and chronic rhinosinusitis or nasal polyps. Use of these agents in younger children with mild episodic wheeze is probably safe. 4) Paracetamol use is probably safe, but aspirin-exacerbated respiratory disease may occur with clinical doses in a subgroup of aspirin-exacerbated respiratory disease patients. COX-2 selective inhibitors are probably safe, although this is controversial. Opioids and tramadol are suitable analgesic alternatives for patients with known or suspected susceptibility.

EFFICACY AND SAFETY OF VISCOSUPPLEMENTATION WITH HYLAN G-F 20 FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

2003 ◽  
Vol 19 (1) ◽  
pp. 41-56 ◽  
Author(s):  
Mireia Espallargues ◽  
Joan M. V. Pons
Keyword(s):  
Knee Osteoarthritis ◽  
Knee Replacement ◽  
Scientific Evidence ◽  
Comparable Efficacy ◽  
Joint Function ◽  
Short Term ◽  
Oral Nsaid ◽  
Clinical Series ◽  
Pain Symptoms

Objectives: To review the scientific evidence on the efficacy, effectiveness, and safety of intra-articular injections of Hylan G-F 20 for the treatment of knee osteoarthritis.Methods: Systematic review of experimental and observational studies performed in humans up to December 1999. Qualitative and quantitative (meta-analytic) techniques were used for data synthesis.Results: A single course of intra-articular Hylan G{-}F 20 provides a statistically significant and clinically relevant short-term decrease of the painful symptomatology of knee osteoarthritis and improves joint function. It also seems to delay the need for knee replacement, if results observed in noncontrolled studies are confirmed. Hylan G-F 20 has a comparable efficacy to that of oral NSAID, and a smaller risk of gastrointestinal adverse effects. It seems to be well tolerated and safe, but the short follow-up in most studies limits any extrapolation of the effectiveness and safety over the longer term. There is also scarce evidence on the effect of multiple courses of Hylan G-F 20, and the scientific rigor of both experimental and nonexperimental studies reviewed is somewhat limited.Conclusions: Whereas there is good quality scientific evidence showing that Hylan G-F 20 is a safe and well-tolerated therapy providing a short-term decrease of the pain symptoms while improving joint function, the delay of the need for knee replacement as well as the durability of the effect over the longer term have only been demonstrated in noncontrolled clinical series. The available evidence is not sufficient to reach firm conclusions on the effect of multiple courses of intra-articular injections of Hylan G-F 20 on health outcomes.

scholarly journals Evaluating signals generated in a large-scale sequence symmetry analyses: macrolides and heart failure; and NSAIDs and pneumonia

2020 ◽  
Author(s):  
SJ Sinnott ◽  
KJ Lin ◽  
S Wang ◽  
J Hallas ◽  
R Desai ◽  
...  
Keyword(s):  
Heart Failure ◽  
Propensity Score ◽  
Large Scale ◽  
Proportional Hazards ◽  
Secondary Analysis ◽  
Cox Proportional Hazards ◽  
Oral Nsaid ◽  
Hazard Ratios ◽  
Amoxicillin Clavulanate ◽  
Topical Diclofenac

AbstractObjectiveUsing US claims data and the most up-to-date pharmacoepidemiological study design tools we aimed to investigate two safety signals for (1) macrolides and heart failure; and (2) non-steroidal anti-inflammatory drugs (NSAIDs) and pneumonia generated from a large-scale screening analysis using a self-controlled sequence symmetry design in Danish data.MethodsWe used IBM Marketscan data to conduct two new-user, active-comparator cohort studies. In the macrolides example, the exposure was clarithromycin or azithromycin and the comparator was amoxicillin/clavulanate, in patients with sinusitis. In the NSAIDs example, the exposure was oral NSAIDs and the comparator was topical diclofenac, in patients with osteoarthritis. We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) to adjust for approximately 50 investigator-specified confounders in a propensity score (PS) matched analysis. In a secondary analysis, we used high-dimensional PS (hd-PS) to adjust for 200 additional proxy confounders.ResultsWe had 1,012,364 propensity score matched patients exposed to clarithromycin or azithromycin versus amoxicillin/clavulanate. With 162 outcomes among clarithromycin or azithromycin exposed patients and 134 among amoxicillin/clavulanate, the HR for overall heart failure was 1.14 (95% CI 0.90 – 1.43). In the NSAIDs example, we included 94,490 patients after propensity score matching. With 794 pneumonia outcomes among oral NSAID patients and 700 among topical diclofenac, we found HR 0.98 (95% CI 0.89 – 1.09). Some upward bias was suspected as larger HRs were observed in the days immediately following exposure for both the macrolides and NSAIDs examples. We found similar results in the hd-PS matched analyses for both examples.ConclusionOur findings for NSAIDs and pneumonia suggest the original signal may have been due to protopathic or detection bias. Our analyses for macrolides and heart failure with short-term follow-up also suggest bias, although we encourage further research.

scholarly journals POS1088 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE OR HIP: A POST-HOC SUBGROUP ANALYSIS OF PATIENTS FROM A RANDOMIZED, NSAID-CONTROLLED STUDY WITH A HISTORY OF DEPRESSION, ANXIETY, OR INSOMNIA

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 823-824
Author(s):  
P. J. Mease ◽  
T. Mallick-Searle ◽  
E. Johnston ◽  
L. Viktrup ◽  
D. Menuet ◽  
...  
Keyword(s):  
Pain Relief ◽  
Physical Function ◽  
Controlled Study ◽  
Womac Pain ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Oral Nsaid ◽  
History Of ◽  
Post Hoc ◽  
History Of Depression

Background:Tanezumab is a monoclonal antibody directed against nerve growth factor. It is in development for the treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom other treatments are ineffective or not appropriate. Phase 3 clinical trials have demonstrated the efficacy of subcutaneous tanezumab versus placebo for pain and function outcomes over various timepoints. Largely similar change from baseline was demonstrated in an oral nonsteroidal anti-inflammatory drug (NSAID)-controlled study.1,2,3,4 The efficacy of some other OA therapies can be dampened in patients with depression, anxiety, or insomnia.5,6,7Objectives:A post-hoc analysis to explore the efficacy of subcutaneous tanezumab after 16 weeks treatment, as compared to oral NSAID, in patients with OA and a history of depression, anxiety, or insomnia at baseline.Methods:Subgroup analysis of data from a randomized, double-blind, double-dummy, active-controlled phase 3 study of subcutaneous tanezumab (2.5 mg or 5 mg every 8 weeks) vs twice daily oral NSAID in patients (≥18 years) with radiographically-confirmed moderate to severe hip or knee OA (Kellgren-Lawrence grade ≥2; NCT02528188).4 Co-primary efficacy endpoints were change from baseline to week 16 in Western Ontario and McMaster Universities OA Index (WOMAC*) Pain and Physical Function subscale scores (both ≥5/10 at randomisation; increasing score indicates increasing pain/disability), and Patient’s Global Assessment of OA (PGA-OA, ≥3/5 at randomisation; increasing score indicates poorer condition). Enrolled patients had a history of inadequate pain relief with acetaminophen; inadequate pain relief with/intolerance to/contraindication to tramadol or opioids; or an unwillingness to take opioids. Patients were on a stable dose of NSAID for ≥30 days before screening. Data are presented as least squares (LS) mean change from baseline to week 16 for the whole population and for subgroups of patients with/without a history of depression, anxiety, or insomnia at baseline. Exploratory statistical analysis was conducted by analysis of covariance. P values were not adjusted for multiplicity. This exploratory post-hoc analysis was not part of the pre-specified hypothesis testing plan or included in any sample size calculations; therefore, comparisons between treatment arms or patient subgroups should be interpreted with caution.Results:Overall, 2996 patients were randomized and received at least one dose of study treatment (subcutaneous tanezumab 2.5 mg: n=1002; subcutaneous tanezumab 5 mg: n=998; oral NSAID: n=996). In this population (comprising patients with or without a history of anxiety, depression or insomnia), all treatments were associated with notable and largely similar magnitude improvements in WOMAC Pain, WOMAC Physical Function, and PGA-OA at week 16 (Figure 1). Across treatment groups, differences in LS mean change from baseline in patients with and without a history of depression, anxiety or insomnia ranged between 0 - 0.34 for WOMAC Pain and Physical Function and 0 - 0.19 for PGA-OA.Conclusion:Patients with a history of depression, anxiety, or insomnia did not appear to experience dampened improvements in pain or function with tanezumab or NSAID, as compared to those without.References:[1]Schnitzer T, et al. JAMA. 2019;322(1):37-48;[2]Berenbaum F, et al. Ann Rheum Dis. 2020;79(6):800-10;[3]Schnitzer T, et al. Semin Arthritis Rheum. 2020;50(3):387-93;[4]Hochberg M, et al. Arthritis Rheumatol. In Press;[5]Sharma A, et al. Open Access Rheumatol. 2016;31(8):103-13;[6]Mallen C, et al. PLoS Med. 2017;14(4):e1002273;[7]Campbell C, et al. Arthritis Care Res. 2015;67(10):1387-96.Acknowledgements:Study sponsored by Pfizer and Eli Lilly and Company. Editorial support was provided by Jennifer Bodkin of Engage Scientific Solutions and funded by Pfizer and Eli Lilly and Company.Disclosure of Interests:Philip J Mease Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Theresa Mallick-Searle Speakers bureau: Allergan, Abbvie, Eli Lilly and Company, Salix, Consultant of: Pfizer, Eli Lilly and Company, Elizabeth Johnston Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Dominique Menuet Employee of: Pfizer, Ruoyong Yang Employee of: Pfizer, Robert J Fountaine Shareholder of: Pfizer, Employee of: Pfizer.

scholarly journals Pengaruh Pengetahuan Masyarakat Terhadap Rasionalitas Penggunaan Analgesik Oral Non Steroid Anti-Inflamatory Drug Golongan Non Selective COX-1 dan COX-2 Secara Swamedikasi

2017 ◽  
Vol 2 (2) ◽  
pp. 24-29
Author(s):  
Haris Imro’atul Husna ◽  
Damaranie Dipahayu
Keyword(s):  
Confidence Level ◽  
Self Medication ◽  
Chi Square ◽  
Rational Use ◽  
Oral Nsaid ◽  
Statistical Application ◽  
Level Of Knowledge ◽  
Cox 2 ◽  
Education And Employment ◽  
Cox 1

ABSTRAKPenelitian ini dilakukan untuk melihat adanya pengaruh tingkat pengetahuan terhadap rasionalitas pasien dalam menggunakan obat oral analgesik NSAID golongan Non Selektif COX-1 & COX-2 pada pengobatanswamedikasi di Apotek Latansa Sidoarjo serta untuk mengetahui adanya pengaruh antara faktor sosiodemografi (usia, jenis kelamin, tingkat pendidikan dan status pekerjaan) terhadap tingkat pengetahuan dan rasionalitas penggunaan obat oral analgesik NSAID Non Selektif COX-1 & COX-2 pada pengobatan swamedikasi di Apotek Latansa Sidoarjo. Penelitian ini merupakan jenis penelitian deskriptif observasional melalui pembagiankuesioner kepada 70 pasien sebagai sampel. Pengumpulan data dilakukan secara prospektif. Hubungan antaravariabel penelitian dianalisis dengan uji statistik Chi Square pada aplikasi statistik SPSS ver 22. Hasil penelitian menunjukkan bahwa responden sebagian besar memiliki pengetahuan yang baik (71,50%) dan swamedikasiyang rasional (75,70%). Tingkat pendidikan menunjukkan adanya pengaruh dengan tingkat pengetahuan (Asymp sig (2-sided) = 0,042 ≤ 0,050) pada tingkat kepercayaan 95%. Dan usia menunjukkan adanya pengaruh dengan rasionalitas penggunaan obat oral analgesik NSAID Non Selektif COX-1 & COX-2 dalam pengobatan swamedikasi (Asymp sig (2-sided) = 0,049 ≤ 0,050) pada tingkat kepercayaan 95%.Hasil analisis dengan uji statistik Chi Square menunjukkan adanya pengaruh antara tingkat pengetahuan pasien terhadap rasionalitas penggunaan obat oral analgesik NSAID Non Selektif COX-1 & COX-2 dalam pengobatan swamedikasi (Asymp sig (2-sided) = 0, 016 ≤ 0,050) pada tingkat kepercayaan 95%.Kata Kunci: swamedikasi, pengetahuan & rasionalitas, analgesik NSAID COX-1 dan COX-2.ABSTRACTThis study was conducted to see the effect of society knowledge on rational use of oral NSAID (Non Selective COX-1 & COX-2) self medication in Latansa Apotek Sidoarjo and to investigate the influence ofsociodemographic factors (age, gender, level education and employment status) on the level of knowledge and rational use of oral NSAID (Non Selective COX-1 & COX-2) self medication in the Latansa Apotek Sidoarjo.This observational study is descriptively through the distribution of questionnaires to 70 patients in the sample. The collection of data carried out prospectively. The relationship between variables was analyzed with statistical test Chi Square on statistical application SPSS ver 22. The level of education showed that have significancy on the level of knowledge (Asymp sig (2-sided) = 0.042 ≤ 0.050) at the 95% confidence level. Ages showed that have significancy on with the rational use oral analgesic NSAIDs Non Selective COX-1 and COX-2 in the treatment swamedikasi (Asymp sig (2-sided) = 0,014 ≤ 0.050) at the 95% confidence level.The result of this study showed that (71,50%) of respondent have good knowledge on NSAID while 75,70% of respondents have appropiate NSAID self-medication behaviors. The statistic analysis showed that knowledge had a significancy on self-medication behavior (Asymp sig (2-sided) = 0, 016 ≤ 0,050) and confidence level 95%.Keywords: Self – medication, Rational use &Knowledge, Analgesic – Non Selective NSAIDS COX-1 And COX-2

Sign in / Sign up

Export Citation Format

Share Document